Bayer (BAYRY) and Souffle Therapeutics announced a strategic collaboration and global licensing agreement to advance a heart-targeted small interfering RNA therapy. The companies will collaborate to develop a siRNA-based treatment for a form of dilated cardiomyopathy. Souffle engineers cell-specific ligands to facilitate the precise delivery of siRNA-based medicines across cell membranes and directly in to target cells. By combining proprietary methods for identifying cell-specific receptors, optimizing ligands, and engineering potent siRNA, Souffle aims to create safer, stronger, and more durable therapeutic options. Financial details of the collaboration have not been disclosed.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BAYRY:
- Bayer’s BAY3018250 DVT Study Reaches Completion: What It Means for Investors
- Barclays upgrades Bayer to Overweight on possible litigation overhang resolution
- Bayer upgraded to Overweight from Equal Weight at Barclays
- Bayer added to European Conviction List at Goldman Sachs
- Bayer Tests Talcid in Real-World Acid Rebound Study: What It Means for BAYRY Investors